Case Manager Shontae talking with a patient

We’re Here to Help Your Patients

Hi, I’m Shontae

Dedicated Case Manager

Call Shontae at 1-833-256-2748

Monday - Friday

8am - 6pm ET

More on the Team

Options for Getting Started

In order to make the process convenient for you and your patient, Alnylam Assist® provides three separate options
for initiating and completing the Start Form.

Alnylam Assist® electronic Start Form circle

Complete and submit the electronic Start Form with your patient

Get Started


Alnylam Assist® Print Start Form circle

Print, complete with your patient, and fax the Start Form to 1-833-256-2747

Download (English)


Alnylam Assist® DocuSign Start Form circle

Begin the Start Form and send to your patient over email to complete via DocuSign

Get Started


Discover More

Patient Services

Learn more about how Alnylam Assist® supports
patients being treated with ONPATTRO® (patisiran).

Get the Facts

Forms and Documents

For more information about Alnylam Assist®
and treatment with ONPATTRO.

See Materials

Alnylam Assist® - Support Team

Take Action Now

Together with your patient (in office)

Important Safety Information

Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO® (patisiran). In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed. 

Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).


ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about ONPATTRO, please see the full Prescribing Information.